Melior Discovery

Melior Discovery is a specialized preclinical CRO that leverages its extensive library of over 150 validated in vivo disease models across 14 therapeutic areas to provide efficacy testing and drug repositioning services. The company differentiates itself through its proprietary phenotypic screening platforms, thera TRACE® and opioid TRACE®, which systematically test compounds in diverse disease models to identify novel therapeutic applications. Operating as a service provider, Melior generates revenue by partnering with biopharma companies, while also using its platform to build its own internal pipeline under the separate entity Melior Pharmaceuticals. The company has established a strong reputation, evidenced by industry recognition and long-term collaborations with top pharmaceutical leaders.

Proprietary in vivo phenotypic screening platforms (thera TRACE® and opioid TRACE®) for systematic drug repositioning. These platforms screen compounds in parallel across a diverse panel of over 150 validated rodent disease models to identify novel therapeutic indications without a pre-defined molecular target hypothesis.

Melior competes with large, full-service preclinical CROs (e.g., Charles River, Labcorp) and smaller niche pharmacology providers. Its differentiation lies in its exclusive focus on in vivo phenotypic screening for drug repositioning, a specialized capability not offered by most broad-based CROs. It competes on scientific depth, model validation, and a proven track record of discovery.